J
Josep M. Guardiola
Researcher at Autonomous University of Barcelona
Publications - 42
Citations - 946
Josep M. Guardiola is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Ribavirin & Hepatitis C. The author has an hindex of 17, co-authored 41 publications receiving 902 citations. Previous affiliations of Josep M. Guardiola include Hospital de Sant Pau.
Papers
More filters
Journal ArticleDOI
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.
Marina Núñez,Celia Miralles,Miguel Angel Berdún,Elena Losada,Koldo Aguirrebengoa,Antonio Ocampo,Piedad Arazo,Manuel Cervantes,Ignacio Santos,Santiago Echeverría,María José Galindo,Victor Asensi,Pablo Barreiro,Julio Sola,Juan Jose Hernandez-Burruezo,Josep M. Guardiola,Miriam Romero,Javier García-Samaniego,Vincent Soriano +18 more
TL;DR: The use of RBV 1000-1200 mg/day plus pegIFN is relatively safe and provides SVR in nearly half of coinfected patients, twice as high in HCV-2/3 thanHCV-1/4.
Journal ArticleDOI
Sustained Virological Response to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus
Juan Berenguer,Elena Urbaneja Rodríguez,Pilar Miralles,Miguel A. Von Wichmann,José López-Aldeguer,Josep Mallolas,María José Galindo,Eva Van den Eynde,María Jesús Téllez,Carmen Quereda,Antoni Jou,José Sanz,Carlos Barros,Ignacio Santos,Federico Pulido,Josep M. Guardiola,Enrique Ortega,Rafael Rubio,Juan J. Jusdado,María Luisa Montes,Gabriel Gaspar,Herminia Esteban,José María Bellón,Juan González-García +23 more
TL;DR: The findings suggest that eradication of HCV after therapy with interferon plus ribavirin in HIV/HCV-coinfected patients is associated not only with a reduction in liver-related events but also with a reduced in HIV progression and mortality not related to liver disease.
Journal ArticleDOI
Drug resistance in patients experiencing early virological failure under a triple combination including indinavir.
Oscar Gallego,Carmen de Mendoza,María J Pérez-Elías,Josep M. Guardiola,José Pedreira,David Dalmau,Juan R. González,Ana Moreno,Jose R. Arribas,Amalia Rubio,Isabel García-Arata,Manuel Leal,Pere Domingo,Vincent Soriano +13 more
TL;DR: Resistance to nucleoside analogues was more frequent than resistance to indinavir; treatment intensification in those patients without resistance, or a selective substitution of nucleosides in those with resistance limited to these compounds, might be justified.
Journal ArticleDOI
Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.
Juan Berenguer,Elena Rodriguez-Castellano,Ana Carrero,Miguel A. Von Wichmann,Marta Montero,María José Galindo,Josep Mallolas,Manuel Crespo,María Jesús Téllez,Carmen Quereda,José Sanz,Carlos Barros,Cristina Tural,Ignacio Santos,Federico Pulido,Josep M. Guardiola,Rafael Rubio,Enrique Ortega,María Luisa Montes,Juan J. Jusdado,Gabriel Gaspar,Herminia Esteban,José María Bellón,Juan González-García +23 more
TL;DR: The data suggest that eradication of HCV in coinfected patients is associated not only with a reduction in the frequency of death, HIV progression, and liver‐related events, but also with a reduced hazard of diabetes mellitus and possibly of chronic renal failure.
Journal ArticleDOI
Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.
Juan Berenguer,Francisco Xavier Zamora,Teresa Aldámiz-Echevarría,Miguel A. Von Wichmann,Manel Crespo,José López-Aldeguer,Ana Carrero,Marisa Montes,Carmen Quereda,María Jesús Téllez,María José Galindo,José Sanz,Ignacio Santos,Josep M. Guardiola,Carlos Barros,Enrique Ortega,Federico Pulido,Rafael Rubio,Josep Mallolas,Cristina Tural,Juan J. Jusdado,Gloria Perez,Cristina Diez,Julio Álvarez-Pellicer,Herminia Esteban,José María Bellón,Juan González-García,Grupo de Estudio del Sida (Gesida) Hiv +27 more
TL;DR: FIB-4 outperformedLB as a predictor of overall death and liver-related events in patients with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection and calls into question the role of LB as a gold standard for assessing prognosis in HIV/HCV coinfections.